Australian journal of general practice · 2025
Palliative management of type 2 diabetes mellitus in patients with advanced cancer.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Weerasinghe Aanjanee, Good Phillip, Stokes Claire, Chen Jones, Gurgenci Taylan
Аннотация
BACKGROUND: Patients with advanced cancer often have type 2 diabetes mellitus (T2DM) and are on multiple medications that affect glycaemic control. Patients can have pre‑existing diabetes or treatment- and glucocorticoid-induced hyperglycaemia. Optimal management of glycaemic control differs at varying stages of life and depends on overall goals of care.
OBJECTIVE: This article summarises the evidence-based management of T2DM in patients with advanced cancer, including management of glucocorticoid-induced hyperglycaemia, and appropriate targets for glycated haemoglobin (HbA1c).
DISCUSSION: T2DM often co-exists in patients with advanced cancer. Management is aimed at reducing the complications of hyperglycaemia and hypoglycaemia, and maximising quality of life. Interventions and treatments need to be balanced against quality of life and prognosis.
OBJECTIVE: This article summarises the evidence-based management of T2DM in patients with advanced cancer, including management of glucocorticoid-induced hyperglycaemia, and appropriate targets for glycated haemoglobin (HbA1c).
DISCUSSION: T2DM often co-exists in patients with advanced cancer. Management is aimed at reducing the complications of hyperglycaemia and hypoglycaemia, and maximising quality of life. Interventions and treatments need to be balanced against quality of life and prognosis.